Efficacy Information

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck

SINGULAIR demonstrated significant efficacy across many clinical studies(1–4)

In chronic asthma
SINGULAIR significantly reduced1,2
  • β-agonist use
  • Asthma attacks
  • Daytime asthma symptoms
  • Nighttime asthma symptoms

In chronic asthma during allergy season
SINGULAIR demonstrated efficacy3
  • β-agonist use
  • AM PEFR
  • Daytime asthma symptoms
  • Discontinuations due to asthma (not significant vs placebo)

Versus an ICS monotherapy (beclomethasone)
Study end points included4
  • Mean FEV1
  • Asthma control days
  • Time to first asthma attack

Prescribe SINGULAIR now to help prevent asthma symptoms
1.
Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB, for the Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213–1220.
2.
Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DA-SNG1(10).
3.
Busse WW, Casale TB, Dykewicz MS, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol. 2006; 96:60–68.
4.
Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DA-SNG17(5).

Important Information

SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.

SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.

Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.

Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

Patients should be advised to take SINGULAIR daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physician if their asthma is not well controlled.